AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Fasenra (benralizumab) — US product sales by Year
Fasenra (benralizumab) — US product sales ($M) ($M)
AstraZeneca Fasenra (benralizumab) — US product sales: $1,195M in FY2025, up 13.9% from a year earlier.
Where the FY2025 figure comes from
“|| Fasenra | 1,981 | 17 | 16 | 1,195 | 14 | 117 | 27 | 29 | 482 | 19 | 15 | 187 | 29 | 30”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fasenra (benralizumab) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,195 | +13.9% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 1,049 | +5.7% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 992 | +9.5% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 906 | +14.7% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 790 | +31.0% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 603 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up fasenra (benralizumab) — US product sales
Cite this data
StockData. (2026). AstraZeneca Fasenra (benralizumab) — US product sales ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-fasenra-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.